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Elective versus symptomatic antibiotic treatment
in cystic fibrosis patients with chronic
Pseudomonas infection of the lungs
J S Elborn, R J Prescott, B H R Stack, M C Goodchild, J Bates, C Pantin, N Ali, D J Shale,
M Crane, on behalf of the British Thoracic Society Research Committee
Abstract
Background—A previous retrospective
study suggested that a policy of regular
anti-pseudomonal antibiotic treatment im-
proved pulmonary function and increased
survival in patients with cystic fibrosis
chronically infected with Pseudomonas
species. The results of a prospective multi-
centre study to compare the eVects on pul-
monary function and mortality of three
monthly elective anti-pseudomonal anti-
biotic treatment with conventional sympto-
matic treatment are reported.
Methods—Sixty patients with cystic fibro-
sis, chronically infected with P aerugi-
nosa, were randomised to the two
treatment arms (elective or symptomatic)
and followed clinically at yearly reviews.
The major end points were changes in
forced expiratory volume in one second
(FEV1) and forced vital capacity (FVC).
Survival was a secondary end point.
Results—Patients in the symptomatic
group received a mean of three antibiotic
treatments each year and those in the elec-
tive group received four antibiotic treat-
ments during each year of the study. No
significant diVerences in FEV1 and FVC
were found between the two groups after
three years. There was a statistically
non-significant higher rate of deaths in the
elective group (n = 4), three of which were
associated with B cepacia infection, com-
pared with the symptomatic group (n = 0).
Conclusions—This study did not demon-
strate an advantage of a policy of elective
antibiotic treatment over symptomatic
treatment in patients with cystic fibrosis
chronically infected with Pseudomonas
species.
(Thorax 2000;55:355–358)
Keywords: cystic fibrosis; Pseudomonas aeruginosa;
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The prognosis for patients with cystic fibrosis
has improved significantly over the past three
decades.1 2 In the 1960s the median survival
age was about six years compared with the cur-
rent median survival age of over 30 years.2 The
care of patients in specialised centres, improved
nutrition, and the aggressive treatment and
control of respiratory infection are considered
to be the main reasons for this improvement.3 4
Patients with cystic fibrosis have frequent
infections during the first decade due mainly to
Staphylococcus aureus and Haemophilus
influenzae.5 By the end of the second decade
the lungs of most patients become colonised
with Pseudomonas aeruginosa and, in some
cases, Burkholderia cepacia.5–7 Aggressive anti-
biotic treatment after the first sputum isolation
of P aeruginosa can postpone chronic infection
but usually this organism is regularly isolated
from sputum culture.8 9 Once established, this
infection causes respiratory exacerbations
which usually respond to treatment with anti-
pseudomonal antibiotics such as ureidopenicil-
lins, aminoglycosides, third or fourth genera-
tion cephalosporins, and carbapenems.10 11
When patients develop an exacerbation of
symptoms, treatment with appropriate antibi-
otics results in a significant improvement in
symptoms and pulmonary function and in a
reduction in systemic markers of the inflamma-
tory response such as C reactive protein and
neutrophil elastase á1-antitrypsin complexes.
12
In 1976 the Danish Cystic Fibrosis Centre
began treating patients colonised with P aerugi-
nosa with a regimen of two week courses of intra-
venous antibiotics given every three months
regardless of their clinical state.13 In a retrospec-
tive comparison of mortality with that occurring
during the previous five years they found a
reduction in deaths from about 10% to 2% per
year and an improvement in five year survival
from 54% to 82%.13 This study was not prospec-
tive or randomised and a large proportion of the
patients were children. During the period of the
study there were several other changes in the
management of cystic fibrosis that have been
shown to improve survival—for example, the
change from low to high fat diets.14 As a result,
survival of patients in most developed countries
improved between 1970 and 1985 and it was
diYcult to assess how much this improvement
was due to a change in antibiotic policy.1
Many centres now advocate regular three
monthly antibiotic treatment without evidence
of eYcacy from a randomised controlled trial.15
We have compared the three year outcome
of regular three monthly elective antibiotic
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treatment with that of antibiotic treatment given
according to symptoms in a prospective ran-
domised parallel group study over three years.
Methods
The study began in 1991 when all cystic fibro-
sis centres in the UK were invited to enter
patients. Patients aged eight years and over
with cystic fibrosis from whom P aeruginosa
had been isolated on three or more occasions
during the previous 12 months were eligible for
inclusion. Informed consent was obtained from
patients and, in those under 16 years of age,
from their parents. Patients with a history of
hypersensitivity to antipseudomonal agents,
those who were already on a regular treatment
regimen of intermittent antibiotics, and those
who had had less than two or more than four
exacerbations during the previous year requir-
ing intravenous antibiotics were excluded.
Patients who agreed to take part were then
allocated by a central coordinating centre to
receive elective antipseudomonal antibiotics
every three months or to receive antibiotic
treatment only when symptoms indicated.
Allocation of treatment was by the method of
minimisation using age, severity based on chest
radiographic score, and treatment centre.
Patients received treatment for 10–14 days
with antipseudomonal antibiotics. The choice
of antibiotic was based on the sensitivity of the
individual patient’s micro-organisms from the
last available sputum culture. A table of
guidance was given for treatment with antibiot-
ics which included the ureidopenicillins, anti-
pseudomonal third generation cephalosporins,
carbapenems, aminoglycosides, monobactams,
and ciprofloxacin. The choice of the place of
treatment was left to the judgement of the indi-
vidual clinician and patients. If a patient in the
elective arm received a course of antibiotics for
a symptomatic deterioration within four weeks
of the planned elective treatment, that course
was taken to be their elective treatment. The
next course of elective treatment was given
three months later. An exacerbation was not
pre-defined in the protocol but left to the
discretion of each centre.
Clinical and lung function data were collected
at the time of entry and at the time of each
annual assessment following entry to the study
when patients were clinically stable. Chest
radiographs were scored independently by a
radiologist experienced in radiology in cystic
fibrosis using the Chrispin-Norman system.
Weight, height, and spirometric values were
recorded as actual values and as standardised
values; percentage of predicted values for
spirometry and number of standard deviations
from the mean of healthy subjects for weight
and height (Z score). A sputum sample was
cultured for respiratory organisms including H
influenzae, S aureus, P aeruginosa and B cepacia
and in vitro sensitivity testing was performed
using the disc diVusion method.
DATA ANALYSIS
The eVect of the treatment group on changes
in the clinical outcome measures from entry to
the study to three years after randomisation
was analysed by analysis of covariance, with the
entry value included as a covariate. The analy-
sis was conducted according to the principle of
intention to treat.
The target sample size for the study was 100
patients. It was anticipated that the standard
deviation of the change in lung function,
expressed as percentage predicted, would be
between 10% and 15%. This would yield a
standard error for the mean diVerence between
the treatment groups of 2–3%. In practice, 60
patients were recruited, inflating the standard
errors by 30% relative to that anticipated.
Results
Sixty patients were entered from 15 cystic fibro-
sis centres, 32 of whom were randomised to the
elective group and 28 to the symptomatic group.
At the start of the study there were no
appreciable diVerences between the two groups
in any of the variables recorded (table 1). Both
groups were receiving similar concomitant
treatments such as antistaphylococcal antibiot-
ics; 25% of patients in the elective group were
taking nebulised antibiotics compared with 40%
in the symptomatic group, while 41% of elective
patients and 29% of symptomatic patients were
taking regular inhaled bronchodilators. None of
these diVerences was significant. There was no
diVerence in the prevalence of pancreatic insuf-
ficiency, diabetes mellitus, significant renal or
liver disease, allergic bronchopulmonary asper-
gillosis, B cepacia infection, or history of
pneumothorax between the two groups at the
time of entry into the study.
ANTIBIOTIC TREATMENTS
The elective group received an average of four
courses of antibiotics per year during the three
years of follow up compared with an average of
three courses per year in the symptomatic
group (table 2). This diVerence was statistically
significant in year 1 but not so in the
subsequent two years.
In the elective group 25 of 30 patients during
year 1, 26 of 31 in year 2, and 22 of 27 in year
3 received three or more courses of antibiotics
Table 1 Comparison of elective and symptomatic groups at entry
Elective (n = 32, 16 male) Symptomatic (n = 28, 13 males)
Age (years) 18 (9) 18 (8)
Height (cm)
(Z score)
157 (17)
–0.5 (1.0)
155 (16)
–0.4 (1.0)
Weight (kg)
(Z score)
47 (13)
–0.5 (1.0)
47 (14)
–0.3 (0.9)
Chrispin-Norman score 11 (5) 10 (4)
Shwachman score 68 (14) 74 (13)
FEV1 (l)
FEV1 (% predicted)
1.7 (0.8)
59 (24)
1.9 (0.9)
63 (25)
FVC (l)
FVC (% predicted)
2.6 (1.1)
72 (21)
2.6 (1.2)
74 (21)
Values are mean (SD).
Z = standard deviation score; FEV1 = forced expiratory volume in one second; FVC = forced vital
capacity.
Table 2 Mean (SD) number of courses of antipseudomonal
antibiotics in each year
Elective Symptomatic
Year 1 4.2 (1.7) 2.9 (1.5)
Year 2 4.1 (2.0) 3.3 (2.5)
Year 3 4.0 (2.0) 3.0 (2.0)
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compared with 18 of 28, 18 of 27, and 14 of 27,
respectively, in the symptomatic group.
CLINICAL OUTCOMES
The changes in lung function, Shwachman
score, Chrispin-Norman radiographic score,
height and weight scores, and weight for height
as a percentage of predicted at the end of three
years are shown in table 3. There were no signifi-
cant diVerences between the two groups in the
changes in any of these measurements. At the
end of year 1 patients in the elective group
showed a slight improvement in lung function
compared with the symptomatic group. This dif-
ference was not sustained after three years (fig 1).
WITHDRAWALS AND DEATHS
There were four deaths and five withdrawals in
the elective group and no deaths and only one
withdrawal in the symptomatic group. All
deaths were due to respiratory failure second-
ary to cystic fibrosis. In the elective group three
patients withdrew from the study because of
the inconvenience of regular antibiotic treat-
ments, one patient because of a heart and lung
transplant, and one patient following preg-
nancy. The patient who withdrew in the symp-
tomatic group did so at his own request. When
the 19 patients in the elective group who com-
pleted three years of intermittent antibiotic
treatment according to the protocol were com-
pared with the symptomatic group there was
also no significant diVerence in any clinical
outcomes described.
SPUTUM MICROBIOLOGY
There was no diVerence at entry to the study in
the number of microbial isolates from sputum of
P aeruginosa which were multiresistant (resistant
to three or more antipseudomonal antibiotics) in
the elective group (n = 7) compared with the
symptomatic group (n = 5). During the
subsequent three years 31 isolates from 15
patients in the elective group and 31 isolates
from 17 patients in the symptomatic group were
due to organisms which were multiresistant. At
entry B cepacia was isolated from two patients in
the elective group but none in the symptomatic
group. Over the subsequent three years 11
isolates of B cepacia were obtained from four
patients in the elective group compared with 13
from five patients in the symptomatic group. In
three of the patients in the elective group B
cepacia was isolated at the time of death. There
was no diVerence in the prevalence of S aureus
and H influenzae between the two groups.
Discussion
In the first three years of this study we have
found no significant advantage of a policy of
regular elective antibiotic treatment over symp-
tomatic treatment in patients with cystic fibro-
sis and chronic infection of the airways. The
main end points of spirometric lung function
(FEV1, FVC) in the elective group and the
symptomatic group were not diVerent after
three years. Other end points such as annual
Chrispin Norman score, Shwachman score,
and body weight were also not diVerent during
the period of study between the two groups.
These results diVer from the retrospective
study from Copenhagen reported by SzaV et al
in 1983.13 In most developed countries survival
improved over that decade without the intro-
duction of any change to elective antibiotic
treatment.1–3 The improvements in survival in
the Danish study could reflect the impact of a
dedicated cystic fibrosis centre, intervention
with improved nutrition, and aggressive anti-
biotic treatment. The patients studied in the
Copenhagen group were probably younger
than in this current study. The mean age is not
quoted but it is likely that it was 12 years com-
pared with 18 years in our study. It is possible
that younger patients may benefit from this
treatment approach more so than adults. How-
ever, in the current study 42% of patients were
under the age of 16 and there has been no sug-
gestion that this younger subgroup behaves
diVerently from older patients.8 In the Copen-
hagen study it is not clear how long elective
antibiotics were started after the first infection
but it is stated that the duration of chronic
infection did not diVer between the elective
and symptomatic groups in the study. A further
diVerence in the Copenhagen study is that the
retrospective control group received one
course of antibiotics to three courses in the
group treated with regular elective antibiotics.
In our prospective study elective antibiotics
did not improve survival. There were more
deaths in the patients treated with elective anti-
biotics than in the symptomatic group, but at
three years this did not reach statistical signifi-
cance. We have continued to collect data for up
Table 3 Changes in clinical outcome measures from entry to end of year 3
Elective Symptomatic
Adjusted diVerence
(95% CI)* p value
FEV1 (% predicted) –5.7 (2.6) –8.1 (3.4) 1.8 (–6.6 to 10.2) 0.67
FVC (% predicted) –5.2 (2.3) –6.3 (4.1) 1.0 (–8.3 to 10.4) 0.83
Shwachman score –4.3 (2.3) –6.1 (2.1) 1.7 (–4.7 to 8.1) 0.59
Chrispin-Norman score –0.8 (0.8) –1.0 (0.8) 0.4 (–1.7 to 2.6) 0.71
Height (SD score) –0.11 (0.13) 0.05 (0.06) –0.06 (–0.33 to 0.22) 0.67
Weight (SD score) –0.06 (0.10) 0.03 (0.09) –0.10 (0.38 to 0.18) 0.49
Weight/height (% predicted) 0 (1.5) –0.8 (1.6) 0.8 (–1.4 to 3.0) 0.72
*Adjusted for entry levels using an analysis of covariance. The signs are such that a positive value
indicates that adjusted values are higher in the elective group at the end of year 3.
FEV1 = forced expiratory volume in one second; FVC = forced vital capacity.
Figure 1 Changes in forced expiratory volume in one second (FEV1) at the end of each
year following randomisation.
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to five years. There is now a significant
diVerence in the number of deaths in the elec-
tive group (n = 8) compared with those treated
symptomatically (n = 1, p<0.04, Fisher’s exact
test). All the deaths were due to cardiopulmon-
ary failure secondary to overwhelming lung
infection. There was no evidence of increased
antibiotic resistance in these patients or
episodes of hypersensitivity. There were slightly
more patients in the symptomatic group who
had B cepacia infection. This organism is asso-
ciated with reduced survival in patients with
cystic fibrosis but does not account for the dif-
ferences in mortality between the groups.17
No significant diVerence in the incidence of
resistant bacteria was found during the study
between the groups and no significant changes
during the time of the study. There is no signifi-
cant diVerence in the incidence of new cases of
multi resistant organisms or new antimicrobial
species such as B cepacia and Stenotrophomonas
maltophilia. This may be because three years is
too short a period of time to monitor changes in
bacterial sensitivity to antibiotics.18
The lack of any diVerence in any of the clini-
cal outcome measures may reflect the design of
this study. Patients who entered the study had at
least two exacerbations requiring intravenous
antibiotics in the year prior to entry. The
patients in the symptomatic arm of the study
received an average of three courses of intra-
venous antibiotics whereas the patients in the
elective arm received an average of four courses
of antibiotics in each year. This suggests that
many patients with cystic fibrosis require
between three and four courses of antibiotics for
respiratory exacerbations and the application of
a policy of regular intravenous antibiotics may
reflect the natural history of the disease.19
This study did not recruit the number of
patients determined in the sample size calcula-
tion, and this reduced the power of the study to
detect a diVerence between the treatment
groups. There was a trend for patients in the
elective arm to have a smaller reduction in
FEV1, FVC, Shwachman score, and Chrispin-
Norman score compared with those treated
symptomatically, but statistical significance
was never reached. The trend towards a diVer-
ence in spirometric values was seen mostly
during the first year. This may reflect a
treatment eVect from the antibiotics or the
early impact on lung function of more frequent
admissions to hospital with extra physiotherapy
and other hospital associated interventions.
There were significantly more withdrawals
by patients treated in the elective arm than in
those having symptomatic treatment. The
major reason for withdrawal from the elective
arm was the extra burden that regular antipseu-
domonal antibiotic treatment places on pa-
tients with cystic fibrosis. Ciprofloxacin was the
only oral antipseudomonal drug available dur-
ing the study. Most of the courses of antibiotics
were given by the intravenous route. One
patient withdrew from the elective arm because
of poor venous access as a result of antibiotic
induced thrombophlebitis.
The policy of elective antibiotic treatment
has a significant cost implication. A course of
intravenous antibiotics given at home costs
approximately £1000 and in hospital may cost
over £3000.10 19 It also has considerable impli-
cations for patients “costing” eight weeks each
year to have the treatment. It is therefore
important that suYcient evidence is available
before committing resources and patients’ time
to this approach. In view of the fact that there
was no significant diVerence between the
elective and symptomatic group, and with the
possibility of increasing resistance to antibiotics
leading to limited therapeutic options, it would
seem prudent to restrict the use of antibiotics to
the treatment of infective exacerbations.
In summary, this study has shown no signifi-
cant advantage in regular elective antibiotic
treatment over symptomatic treatment in
patients with cystic fibrosis with chronic infec-
tion with P aeruginosa. The apparent excess of
deaths in the elective group is disturbing as
there is no obvious explanation. It is important
that further studies in younger patients are
performed.
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